Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NMS-03305293 + Topotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NMS-03305293 | NMS03305293|NMS 03305293|NMS-293|NMS293|NMS 293 | PARP-1 Inhibitor 13 | NMS-03305293 inhibits PARP1, potentially leading to decreased DNA damage repair, increased tumor cell apoptosis, and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12, NCI Thesaurus). | |
| Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06930755 | Phase I | NMS-03305293 + Topotecan | Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | Recruiting | USA | 0 |